Studybox Research 510(k) Clinical Studies
RSV Rapid Antigen Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
RSV antigen tests perform well in infants and young children, who shed virus at high titer, and poorly in adults, who do not. This single fact shapes the clinical study: most RSV antigen tests carry a pediatric-only intended use, and a sponsor who wants an adult claim must be prepared to show sensitivity in a population where antigen detection has historically fallen well short of molecular methods.
Enrollment is therefore pediatric, which brings parental permission, assent where appropriate, pediatric collection technique and sites with high infant and toddler volume during RSV season. Seasons have been less predictable since 2020, and the introduction of maternal vaccination and long-acting monoclonal antibody prophylaxis for infants may lower the proportion of symptomatic infants who present with high viral loads.
- Analyte
- Respiratory syncytial virus antigen (fusion or nucleoprotein target, depending on the device)
- Therapeutic area
- Infectious Disease
- Specimens
- Nasopharyngeal (NP) Swab, Anterior Nares (Nasal) Swab
- Intended-use settings
- urgent care, physician office, hospital POC, emergency department
- Operators
- Pediatric and family practice clinic staff and urgent care staff in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically an FDA-cleared RSV RT-PCR assay on a paired specimen; viral culture and direct fluorescent antibody staining were historical comparators and are rarely used now.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The intended use age range is the key labeling decision; an adult claim requires adult positives analyzed separately and is typically the component that falls short or is dropped.
- RSV A and RSV B subgroup representation among positives is a review point, typically addressed through subtyping of comparator-positive specimens or analytical reactivity data.
- Co-circulation with influenza and SARS-CoV-2 means specificity is tested in a population with similar presentations, which is the right population; cross-reactivity against other respiratory viruses is also addressed analytically.
Endpoints the study must support
- Positive and negative percent agreement against the molecular comparator in the claimed age range, with 95% confidence intervals
- Performance by age stratum (infants, young children and, if claimed, adults) and by specimen type
- Invalid rate and inter-reader agreement for visually read devices
Enrollment realities
Positives in the claimed age range drive sample size; infant and toddler enrollment is limited by season length, parental consent rates and the availability of pediatric sites. Adult positives are rare and typically require a disproportionate number of adult enrollments. RSV season has historically run from fall through winter in most of the United States, with regional variation; timing has been irregular since 2020 and should be tracked with surveillance data.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
RSV Rapid Antigen Test Study Questions.
01 Who operates the rsv rapid antigen test in a 510(k) studies study?
Pediatric and family practice clinic staff and urgent care staff in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a rsv rapid antigen test study?
Typically an FDA-cleared RSV RT-PCR assay on a paired specimen; viral culture and direct fluorescent antibody staining were historical comparators and are rarely used now.
03 What drives enrollment for a rsv rapid antigen test study?
Positives in the claimed age range drive sample size; infant and toddler enrollment is limited by season length, parental consent rates and the availability of pediatric sites. Adult positives are rare and typically require a disproportionate number of adult enrollments. RSV season has historically run from fall through winter in most of the United States, with regional variation; timing has been irregular since 2020 and should be tracked with surveillance data.
Let's talk IVD research
Planning a rsv rapid antigen test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.